Astrazeneca PLC (AZN) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Astrazeneca’s revenue went from $23.0B in fiscal 2016 to $58.7B in fiscal 2025, growth of about 11.0% a year.
Net income in fiscal 2025 was $10.2B, a net margin of 17.4%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $62.4B and net income $11.0B.
Free cash flow was $11.8B in fiscal 2025 and positive in 10 of the 10 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $62.4B | $58.7B | $54.1B | $45.8B | $44.4B | $37.4B | $26.6B | $24.4B | $22.1B | $22.5B | $23.0B |
| Gross profit | — | $48.1B | $43.9B | $37.5B | $32.0B | $25.0B | $21.3B | $19.5B | $17.2B | $18.1B | $18.9B |
| Operating income | — | $13.7B | $10.0B | $8.2B | $3.8B | $1.1B | $5.2B | $2.9B | $3.4B | $3.7B | $4.9B |
| Net income | $11.0B | $10.2B | $7.0B | $6.0B | $3.3B | $112M | $3.2B | $1.3B | $2.2B | $3.0B | $3.5B |
| EPS (diluted) | $7.06 | $6.59 | $4.54 | $3.84 | $2.12 | $0.07 | $2.06 | $0.86 | $1.39 | $1.94 | $2.26 |
| R&D | — | — | — | — | — | — | — | — | — | — | — |
| Revenue growth | — | +8.6% | +18.0% | +3.3% | +18.5% | +40.6% | +9.2% | +10.4% | −1.7% | −2.3% | −6.9% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $13.2B | $14.6B | $11.9B | $10.3B | $9.8B | $6.0B | $4.8B | $3.0B | $2.6B | $3.6B | $4.1B |
| Capital spending | -$7.1B | -$2.8B | -$1.9B | -$1.4B | -$1.1B | -$1.1B | -$961M | -$979M | -$1.0B | -$1.3B | -$1.4B |
| Free cash flow | $6.1B | $11.8B | $9.9B | $9.0B | $8.7B | $4.9B | $3.8B | $2.0B | $1.6B | $2.3B | $2.7B |
| Dividends paid | $5.0B | $5.0B | $4.6B | $4.5B | $4.4B | $3.9B | $3.6B | $3.6B | $3.5B | $3.5B | $3.6B |
| Buybacks | — | $521M | $81M | — | — | $149M | — | — | — | — | — |
| Stock-based pay | — | $719M | $660M | $579M | $619M | $615M | $277M | $259M | $219M | $220M | $241M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $5.7B | $5.7B | $6.0B | $6.4B | $6.4B | $8.0B | $6.2B | $5.7B | $4.6B | $5.9B |
| Debt | — | $29.6B | $30.3B | $28.6B | $29.2B | $30.8B | $20.4B | $18.2B | $19.1B | $17.8B | $16.8B |
| Equity | — | $48.7B | $40.8B | $39.1B | $37.0B | $39.3B | $15.6B | $13.1B | $12.5B | $15.0B | $14.9B |
| Total assets | — | $114.1B | $104.0B | $101.1B | $96.5B | $105.4B | $66.7B | $61.4B | $60.7B | $63.4B | $62.5B |
| Shares (diluted) | 1.56B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 81.9% | 81.1% | 82.0% | 72.1% | 66.8% | 80.1% | 79.8% | 77.7% | 80.8% | 82.1% |
| Operating margin | — | 23.4% | 18.5% | 17.9% | 8.5% | 2.8% | 19.4% | 12.0% | 15.3% | 16.4% | 21.3% |
| Net margin | 17.7% | 17.4% | 13.0% | 13.0% | 7.4% | 0.3% | 12.0% | 5.5% | 9.8% | 13.4% | 15.2% |
| FCF margin | 9.8% | 20.0% | 18.4% | 19.6% | 19.7% | 13.0% | 14.4% | 8.2% | 7.1% | 10.0% | 11.7% |
| ROIC | — | 14.5% | 11.4% | 10.4% | 4.5% | 1.2% | 11.5% | 7.4% | 8.5% | 8.9% | 14.8% |
| ROE | — | 21.0% | 17.2% | 15.2% | 8.9% | 0.3% | 20.5% | 10.2% | 17.3% | 20.1% | 23.6% |
Frequently asked questions
What is Astrazeneca’s annual revenue?
$58.7B in fiscal 2025 and $62.4B over the twelve months to September 30, 2026.
How much profit does Astrazeneca make?
Net income was $10.2B in fiscal 2025 (net margin 17.4%).
Is Astrazeneca’s revenue growing?
Yes: revenue rose 8.6% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.